Issues
-
Cover Image
Cover Image
To escape immune checkpoint blockade's antitumor effects, some cancers downregulate MHC-I, reducing antigen presentation. Gu, Zhang, Wang, Jiang, and colleagues found that TRAF3, a cytoplasmic signal-transduction protein and NFκB pathway inhibitor, was a negative regulator of MHC-I expression. Traf3-knockout mice exhibited enhanced T cell–mediated cytotoxicity toward tumor cells, and immune checkpoint blockade efficacy was enhanced in these mice. Traf3 knockout also resulted in a distinctive transcriptional profile that correlated with the transcriptional profiles of human melanomas that had greater MHC-I expression; patients with these profiles had better median survival. Finally, a drug screen identified birinapant as being capable of mimicking the effects of Traf3 knockout in mice. For more information, see the article by Gu, Zhang, Wang, Jiang, and colleagues on page 1524. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
In This Issue
News in Brief
News in Depth
Research Watch
Metastasis
Epigenetics
Metabolism
Structural Biology
Leukemia
Clinical Trials
Microbiome
Lymphoma
Immunotherapy
Letter to the Editor
In the Spotlight
Perspective
Reviews
Research Briefs
LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms
Loss of LKB1 (also known as STK11) was associated with progression of myeloproliferative neoplasms (MPN) to blast-phase MPN, a serious manifestation of acute myeloid leukemia in mouse models and in patients.
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin
Research Articles
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody–Drug Conjugate
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.